These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2004-001664-50 An open label, phase II multicentre evaluation of the activity and safety of fotemustine administered to patients with recurrent or progressive glioblastoma multiforme. bad-data
Completed, but no date 2004-002712-28 Chronic iloprost administration in scleroderma patients effect on disease progression, as assessed by skin fibrosis evaluation. A randomized, controlled, blind-observer, multicenter phase III study. bad-data
Ongoing 2004-004854-19 A randomized, double-blind, placebo-controlled, parallel group multicenter study to investigate efficacy and safety of ITF 2357 in the management of patients with active moderate to severe Crohn’s dis... not-yet-due
Completed, but no date 2005-001084-56 Phase II Multiple-Dose Clinical Trial of Oral ITF 2357 In Patients with Advanced Multiple Myeloma bad-data
Completed, but no date 2005-005321-63 Multicentre, open label, uncontrolled, pilot, phase II study of oral ITF2357 in subjects with acute myeloid leukemia refractory/resistant and/or not suitable for any alternative therapy bad-data
Not reported 2006-000089-35 Phase II, open label, international, multicentre clinical trial to investigate safety and efficacy of oral ITF 2357 in patients with active systemic onset juvenile idiopathic arthritis SOJIA 2008-08-25 due-trials
Completed, but no date 2006-002113-12 Open label, uncontrolled, pilot, phase II study of histone-deacetylase inhibitor ITF2357 administered orally to subjects aged over 60 years with primary or secondary DLBCL refractory/ relapsed after c... bad-data
Not reported 2006-005465-19 Open label, uncontrolled, pilot, phase II study of histone-deacetylase inhibitor ITF2357 administered orally to subjects with chronic lynphocytic leukemia (CLL) refractory/relapsed after conventional ... 2008-08-12 due-trials
Completed, but no date 2006-005964-24 Pharmacokinetics, pharmacodynamics and safety of a new Leuprolide acetate 22.5 mg depot formulation, when given as palliative treatment to prostate cancer patients bad-data
Completed, but no date 2007-000049-36 Phase II study of the histone-deacetylase inhibitor ITF2357 in very high-risk relapsed/refractory Hodgkin's lymphoma patients bad-data
Completed, but no date 2007-000051-34 Randomized, open-label, controlled and multicenter trial on a new pattern of Paroxetine up-titration for Panic Disorder. Comparison between two different dose regimens. bad-data
Completed, but no date 2007-000189-19 Multicenter, randomized, double-blind, placebo-controlled study to evaluate the effect of ITF2357 on mucosal healing in patients with moderate-to-severe active Crohn’s Disease bad-data
Ongoing 2007-003399-20 Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, para determinar la eficacia y seguridad de una nueva formulación de estriol en baja concentración (ITFE-2... not-yet-due
Completed, but no date 2007-004480-21 A phase IIA study of the histone-deacetylase inhibitor ITF2357 in patients with JAK-2 V617F positive chronic myeloproliferative diseases bad-data
Completed, but no date 2007-007091-41 Phase II Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin’s Lymphoma Patients bad-data
Completed, but no date 2008-000880-40 Paroxetine drops for the switch-therapy in patients chronic users of Benzodiazepines: an experience in Community Medicine bad-data
Not reported 2008-001416-20 Phase II High Pulse Dose Clinical Trial of Orally Administered ITF 2357 In Patients with Relapsed/Refractory Multiple Myeloma 2009-11-11 due-trials
Not reported 2009-010982-22 Phase II study of the histone-deacetylase inhibitor GIVINOSTAT (ITF2357) in combination with hydroxyurea in patients with JAK2V617F positive Polycythemia Vera non-responder to hydroxyurea monotherapy 2011-07-07 due-trials
Not reported 2010-019094-15 A multicenter, open label, dose finding study to evaluate efficacy and safety of Givinostat administered in two different doses in patients with polyarticular course Juvenile Idiopathic Arthritis (pol... 2012-06-01 due-trials
Not reported 2011-003341-18 An Open-Label Extension of the Dose Finding study (DSC/08/2357/36) in patients with polyarticular course Juvenile Idiopathic Arthritis (poly JIA) 2014-01-27 due-trials
Completed, but no date 2012-002566-12 A Two-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, and Effects on Histology and Different Clinical Parameters of Givinostat in Ambulant Children with Duchenne Muscular Dystrophy... bad-data
Ongoing 2012-003499-37 Long-term Study Evaluating the Effect of Givinostat in Patients With JAK2V617F positive Chronic Myeloproliferative Neoplasms not-yet-due
Listed as ongoing, but also has a completion date 2013-000860-27 A two-part study to assess the safety and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia Vera 2017-09-25 bad-data
Listed as ongoing, but also has a completion date 2013-003183-31 A Randomized, Multicenter, Phase II study to Investigate Efficacy and Safety of ITF2984 in Acromegalic patients. 2016-02-08 bad-data
Other 2016-000401-36 Randomised, double blind, placebo controlled, multicentre study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy. not-yet-due
No trial status on register 2017-000397-10 Studio in aperto a lungo termine volto a valutare la sicurezza, la tollerabilità e l'efficacia di GIVINOSTAT in pazienti affetti da distrofia muscolare di Duchenne che sono stati precedentemente tratt... bad-data
Ongoing 2017-001629-41 A randomised, double-blind, placebo-controlled study to evaluate the micro-macroscopic effects on muscles, the safety and tolerability, and the efficacy of not-yet-due